$9.31
-2.92%
N/A-$0.28
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate ...
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate ...
C-레벨 임원은 회사의 재무 전략과 혁신을 이끄는 응집된 리더십 팀입니다.
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| Noah Berkowitz | Chief Medical Officer | USD 834,887 | — | 1964 | Active |
| Andrew Saik | Chief Financial Officer & Treasurer | USD 819,563 | 1969 | Active | |
| Angela Cacace | Chief Scientific Officer | USD 758,163 | 1968 | Active | |
| Randy Teel | CEO, President & Director | USD 711,098 | — | 1980 | Active |
| Jared Freedberg | General Counsel & Corporate Secretary | — | 1969 | Active | |
| Alexander A. Santini | Chief Commercial Officer | — | 1959 | Active | |
| David Loomis | Vice President & Chief Accounting Officer | — | 1974 | Active | |
| Jeff Boyle | Vice President of Investor Relations | — | — | Active | |
| Paul McInulty | Senior Vice President of Regulatory Affairs | — | — | Active | |
| Steve Weiss | Senior Vice President & Chief Human Resources Officer | — | 1970 | Active | |
| Kelly Page | Senior Vice President & Global Head of Oncology Strategy and Program Leadership | — | — | Active |
| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | 2025 | John Houston, Ph.D. | Former Former President President and Chief Chief Executive Officer | Founder / CEO | $706.24K | $0 | $2.69M | $2.67M | $457.00K | $14.00K | $6.53M |
| 2026-04-29 | 2025 | Noah Berkowitz, M.D., Ph.D. | Chief Chief Medical Officer | C-Level | $552.39K | $0 | $1.37M | $1.39M | $268.50K | $14.00K | $3.59M |
| 2026-04-29 | 2025 | Andrew Saik | Chief Chief Financial Officer and Treasurer | C-Level | $542.06K | $0 | $1.26M | $1.28M | $263.50K | $14.00K | $3.36M |
| 2026-04-29 | 2025 | Angela Cacace, Ph.D. | Chief Chief Scientific Officer | C-Level | $500.76K | $0 | $1.26M | $1.28M | $243.40K | $14.00K | $3.30M |
| 2026-04-29 | 2025 | Ian Taylor, Ph.D. | Former Former President President of Research and Development | C-Level | $152.57K | $0 | $364.34K | $362.47K | $0 | $24.02K | $903.39K |
| 2026-04-29 | 2024 | John Houston, Ph.D. | Former Former President President and Chief Chief Executive Officer | Founder / CEO | $684.00K | $0 | $5.85M | $5.77M | $426.82K | $13.80K | $12.75M |
| 2026-04-29 | 2024 | Noah Berkowitz, M.D., Ph.D. | Chief Chief Medical Officer | C-Level | $421.83K | $0 | $2.70M | $2.65M | $197.50K | $13.80K | $5.98M |
| 2026-04-29 | 2024 | Ian Taylor, Ph.D. | Former Former President President of Research and Development | C-Level | $367.94K | $0 | $1.84M | $1.82M | $172.20K | $13.80K | $4.22M |
| 2026-04-29 | 2024 | Andrew Saik | Chief Chief Financial Officer and Treasurer | C-Level | $272.60K | $0 | $1.53M | $1.53M | $127.60K | $4.85K | $3.47M |
| 2026-04-29 | 2024 | Angela Cacace, Ph.D. | Chief Chief Scientific Officer | C-Level | $464.75K | $0 | $1.14M | $1.13M | $217.60K | $13.80K | $2.97M |
| 2026-04-29 | 2023 | John Houston, Ph.D. | Former Former President President and Chief Chief Executive Officer | Founder / CEO | $657.70K | $0 | $2.13M | $4.35M | $473.60K | $13.20K | $7.63M |
| 2026-04-29 | 2023 | Ian Taylor, Ph.D. | Former Former President President of Research and Development | C-Level | $466.86K | $0 | $657.33K | $1.34M | $252.20K | $13.20K | $2.73M |
Sum of disclosed compensation by year (USD million)
Top founder/C-level executives over time (USD million)